查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088703

體外毒性測試市場：依服務類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

In-Vitro Toxicology Testing Market by Service Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，體外毒性測試市場規模將達到 317.3 億美元，複合年成長率為 11.52%。

主要市場統計數據
基準年 2025 147.8億美元
預計年份：2026年 162.1億美元
預測年份：2032年 317.3億美元
複合年成長率 (%) 11.52%

體外毒性測試正從單純的研究輔助工具發展成為製藥、生物技術、化學、化妝品、食品配料和醫療設備等產業開發人員的核心決策平台。這個市場由檢驗的毒性檢測方法、人源細胞模型、3D細胞培養、晶片器官系統、高性能篩檢和計算毒理學等技術共同塑造，這些技術在提高早期安全性預測的同時，也減少了對動物試驗的依賴。

監管政策的發展是推動成長的核心動力。在美國，《FDA現代化法案2.0》取消了藥物在人體臨床試驗前必須進行動物試驗的法律要求。同時，歐盟自2013年起全面禁止化妝品動物試驗，並繼續在2010/63/EU指令中支持3R原則。經合組織（OECD）制定的皮膚腐蝕、皮膚刺激、嚴重眼損傷、眼睛刺激、光毒性、遺傳毒性和內分泌活性測試指南，為非動物試驗方法和新型調查方法的廣泛應用提供了公認的基礎。

測試環境的變革性變化

體外毒性測試領域正經歷一場變革，其驅動力包括法規核准、倫理考量以及人類生物模型的科學進步。儘管傳統的單層細胞培養試驗仍廣泛用於細胞毒性和基因毒性篩檢，但對能夠更真實地模擬人體組織結構、代謝和暴露動態的3D球體、共培養模型、誘導多功能細胞衍生組織、微生理系統和晶片器官平台的需求正在迅速成長。

人工智慧（AI）的累積影響

人工智慧透過將檢測結果與預測模型、化學結構數據、體學資料集、不良事件管道和暴露資訊相結合，提升了體外毒性測試的價值。機器學習支援基於影像的毒性評分、高內涵篩檢、定量構效關係 (QSAR) 建模、劑量反應預測以及化合物的優先排序，以進行驗證性測試。這些應用在篩檢大規模化合物庫、檢測細微的細胞表現型或識別毒性機制方面尤其有用。

主要區域趨勢

隨著中國、印度、日本、韓國、新加坡和澳洲加大對生物製藥研發、合約研究、化妝品安全評估、先進細胞模型和監管科學的投資，亞太地區正成為體外毒性測試的領先中心。北美憑藉著美國食品藥物管理局（FDA）、美國國立衛生研究院（NIH）和美國環保署（EPA）的存在，以及其成熟的合約研究組織（CRO）網路、活躍的生物製藥研究活動和積極主動的研發中心（例如Tox21計畫），繼續保持其作為主要創新中心的地位。 Tox21專案展示如何利用高性能體外篩檢進行化學品安全優先排序。

關鍵小組洞察

東協市場在體外毒性測試領域的重要性日益凸顯。新加坡是生物醫學創新中心，而馬來西亞、泰國、印尼、越南和菲律賓正在擴大藥品、食品和化妝品的生產。海灣合作理事會（GCC）地區也備受關注，沙烏地阿拉伯、阿拉伯聯合大公國及其鄰國正在加大對生命科學、衛生安全、臨床研究基礎設施和品管系統的投資。歐盟憑藉其在化學品和化妝品法規方面的協調統一、REACH法規的實施以及強力的3R（替代、減少、再利用）計劃，仍然是替代毒性評估方法領域最具影響力的監管機構。

主要國家概況

美國憑藉FDA的監管現代化、NIH支持的轉化科學、EPA的化學品測試舉措以及成熟的CRO生態系統，在拉丁美洲發揮主導作用。加拿大受益於其強大的學術毒理學、生物技術叢集以及與OECD方法論的接軌，而墨西哥則正在加強與北美製造業、製藥業、醫療設備和品質檢測網路的聯繫。巴西是拉丁美洲的主要市場，這得益於其在製藥、化妝品、化學和監管科學領域的活躍表現。

為行業領導者提供的實用建議

產業領導者應優先考慮檢驗的檢測方法組合，這些組合應能滿足細胞毒性、基因毒性、皮膚和眼睛刺激性、肝毒性、心臟毒性、免疫毒性、神經毒性和內分泌干擾等高需求終點的檢測要求。投資應重點關注具有清晰監管管道、明確性能標準、參考化學品和完善文件包裝的檢測方法，以支持符合經合組織 (OECD)、美國食品藥品監督管理局 (FDA)、美國環保署 (EPA)、歐洲藥品管理局 (EMA)、歐洲化學品管理局 (ECHA) 和各國監管機構要求的申報。

調查方法

本調查方法結合了來自監管機構、標準化機構、同行評審文獻、專利趨勢、行業協會資料和公開機構資訊來源的二手研究。主要資訊來源包括經合組織測試指南、美國食品藥品監督管理局 (FDA) 和環境保護署 (EPA) 的政策文件、歐盟委員會和歐洲化學品管理局 (ECHA) 的指導文件、美國國立衛生研究院 (NIH) 和 Tox21 的出版刊物、國際標準化組織 (ISO) 品質標準、PubMed 收錄的毒理學研究以及關於新期刊出版物的科學出版物。

結論

隨著監管機構、企業和消費者對更安全、更快速、更貼近人體的毒性評估的需求日益成長，體外毒性測試預計將持續擴展。最大的機會在於將檢驗的檢測方法、先進的細胞模型、自動化技術、高內涵成像和人工智慧分析整合到高度可重複的工作流程中，以滿足監管要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 體外毒性測試市場：依服務類型分類

  • 生化分析
  • 細胞培養實驗
    • 細胞株檢測
    • 原代細胞檢測
  • 計算模型

第8章：體外毒性測試市場：依技術分類

  • 高效能篩檢
    • 檢測基礎
    • 基於成像
  • 微流體技術
  • 器官晶片
  • 3D文化

第9章：體外毒性測試市場：依應用領域分類

  • 化妝品測試
    • 眼睛刺激
    • 皮膚刺激
  • 藥物發現
    • 先導藥物最適化
    • 目標驗證
  • 安全評估
    • 致癌性
    • 細胞毒性
    • 基因毒性

第10章：體外毒性測試市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術

第11章 體外毒性測試市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：體外毒性測試市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：體外毒性測試市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • BioIVT LLC
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • ERBC Group
  • Eurofins Scientific SE
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Gentronix Limited
  • HD Biosciences Co., Ltd.
  • INDIGO Biosciences, Inc.
  • Inotiv, Inc.
  • InSphero AG
  • Intertek Group PLC
  • Laboratory Corporation of America Holdings
  • LAUS GmbH
  • LGC Limited
  • Merck KGaA
  • Microbac Laboratories Inc.
  • Oroxcell
  • Promega Corporation
  • Qiagen NV
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • Toxys, Inc.
  • Vimta Labs Ltd.
  • WuXi AppTec
Product Code: MRR-A339DAEFAF18

The In-Vitro Toxicology Testing Market is projected to grow by USD 31.73 billion at a CAGR of 11.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.78 billion
Estimated Year [2026] USD 16.21 billion
Forecast Year [2032] USD 31.73 billion
CAGR (%) 11.52%

In-vitro toxicology testing is moving from a supporting research tool to a core decision-making platform for pharmaceutical, biotechnology, chemical, cosmetic, food ingredient, and medical device developers. The market is being shaped by validated toxicology assays, human-relevant cell models, 3D cell culture, organ-on-chip systems, high-throughput screening, and computational toxicology that reduce reliance on animal testing while improving early safety prediction.

Regulatory momentum is a central growth driver. The FDA Modernization Act 2.0 removed the statutory requirement for animal testing before human drug trials in the United States, while the European Union has enforced a full cosmetics animal testing ban since 2013 and continues to support the 3Rs principles under Directive 2010/63/EU. OECD test guidelines for skin corrosion, skin irritation, serious eye damage, eye irritation, phototoxicity, genotoxicity, and endocrine activity provide a recognized foundation for broader adoption of non-animal methods and new approach methodologies.

Transformative Shifts in the Testing Landscape

The in-vitro toxicology testing landscape is being transformed by the convergence of regulatory acceptance, ethical expectations, and scientific advances in human biology-based models. Conventional monolayer cell assays remain widely used for cytotoxicity and genotoxicity screening, but demand is accelerating for 3D spheroids, co-culture models, induced pluripotent stem cell-derived tissues, microphysiological systems, and organ-on-chip platforms that better replicate human tissue architecture, metabolism, and exposure dynamics.

End users are also changing how toxicology evidence is generated. Pharmaceutical companies are integrating in-vitro toxicology earlier in discovery to de-risk lead candidates, chemical manufacturers are using integrated approaches to testing and assessment under REACH and OECD frameworks, and cosmetics companies are relying on validated in-vitro methods because animal testing for finished cosmetic products and ingredients is prohibited in the EU. The shift favors providers that combine biological relevance, regulatory documentation, reproducibility, endpoint sensitivity, and scalable assay automation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasing the value of in-vitro toxicology testing by connecting assay outputs with predictive models, chemical structure data, omics datasets, adverse outcome pathways, and exposure information. Machine learning supports image-based toxicity scoring, high-content screening, quantitative structure-activity relationship modeling, dose-response prediction, and prioritization of compounds for confirmatory testing. These applications are especially valuable when screening large chemical libraries, detecting subtle cellular phenotypes, or identifying mechanisms of toxicity.

The cumulative impact of AI is not the replacement of laboratory science but the creation of more efficient, transparent, and evidence-rich toxicology workflows. Leading organizations are combining AI with good laboratory practice, data provenance, model validation, and explainability requirements. Regulatory relevance depends on traceable datasets, defined applicability domains, reproducible algorithms, bias control, and alignment with OECD principles for validated computational models.

Key Regional Insights

Asia-Pacific is becoming a major hub for in-vitro toxicology testing as China, India, Japan, South Korea, Singapore, and Australia invest in biopharmaceutical R&D, contract research, cosmetics safety, advanced cell models, and regulatory science. North America remains a leading innovation center due to the presence of the FDA, NIH, EPA, established CRO networks, high biopharma research activity, and active programs such as Tox21 that demonstrate the use of high-throughput in-vitro screening for chemical safety prioritization.

Europe continues to set the global benchmark for non-animal testing through EU cosmetics restrictions, REACH requirements, ECHA guidance, OECD-aligned validation practices, and long-standing policy support for the 3Rs. Latin America is expanding adoption through pharmaceutical manufacturing, cosmetics demand, food safety testing, and regulatory modernization led by Brazil and Mexico. The Middle East is building demand through healthcare diversification, national biotechnology strategies, and research infrastructure, while Africa is at an earlier adoption stage but shows long-term potential as laboratory capacity, public health testing, and academic-industry collaboration expand.

Key Group Insights

ASEAN markets are increasingly relevant for in-vitro toxicology testing because Singapore anchors biomedical innovation while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand pharmaceutical, food, and cosmetic production. The GCC is gaining visibility as Saudi Arabia, the UAE, and neighboring economies invest in life sciences, health security, clinical research infrastructure, and quality systems. The European Union remains the most influential regulatory group for alternative toxicology methods due to harmonized chemicals and cosmetics rules, REACH implementation, and strong 3Rs policy.

BRICS countries represent scale, manufacturing depth, and growing domestic demand, with China and India particularly important for drug development services, chemical safety testing, and biopharmaceutical research. G7 economies lead in regulatory science, advanced biomanufacturing, biomedical funding, and policy support for new approach methodologies. NATO is not a commercial regulatory bloc, but member alignment on biosecurity, medical countermeasures, and defense health research can indirectly support validated toxicology platforms for emergency preparedness and chemical threat assessment.

Key Country Insights

The United States leads through FDA regulatory modernization, NIH-supported translational science, EPA chemical testing initiatives, and a mature CRO ecosystem. Canada benefits from strong academic toxicology, biotechnology clusters, and alignment with OECD methods, while Mexico is increasingly tied to North American manufacturing, pharmaceuticals, medical devices, and quality testing networks. Brazil is the primary Latin American market due to its pharmaceutical, cosmetics, chemical, and regulatory science activities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine established life science industries with regulatory pressure to reduce animal testing, while Russia maintains demand in pharmaceuticals, chemicals, and public research despite geopolitical constraints. China and India are expanding rapidly through large CRO sectors, domestic drug pipelines, chemical manufacturing, and cosmetics and safety testing requirements. Japan and South Korea emphasize high-quality regulatory science, stem cell research, and advanced cell technologies, and Australia is recognized for biomedical research, clinical development connectivity, and OECD-aligned testing practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated assay portfolios that address high-demand endpoints such as cytotoxicity, genotoxicity, skin and eye irritation, hepatotoxicity, cardiotoxicity, immunotoxicity, neurotoxicity, and endocrine disruption. Investments should focus on assays with clear regulatory pathways, defined performance standards, reference chemicals, and documentation packages that can support submissions across OECD, FDA, EPA, EMA, ECHA, and national authority expectations.

Companies should build integrated testing strategies that combine in-vitro assays, in-silico models, exposure science, adverse outcome pathways, and targeted in-vivo testing only where required. Strategic partnerships with CROs, organ-on-chip developers, automation suppliers, biobanks, and AI analytics providers can shorten validation timelines. Leaders should also implement data governance, FAIR data principles, quality management systems, and explainable AI controls to ensure scientific credibility and regulatory confidence.

Research Methodology

The research methodology combines secondary research from regulatory bodies, standards organizations, peer-reviewed literature, patent trends, industry association materials, and publicly available institutional sources. Core sources include OECD test guidelines, FDA and EPA policy documents, European Commission and ECHA guidance, NIH and Tox21 publications, ISO quality standards, PubMed-indexed toxicology studies, and recognized scientific publications on new approach methodologies.

Market interpretation is developed through triangulation across technology adoption signals, regulatory milestones, end-user demand patterns, regional life science infrastructure, laboratory capability, and expert assessment of validated test methods. The analysis avoids unsupported market-size claims and focuses on verifiable indicators, including policy changes, recognized test guidelines, quality standards, documented assay validation, and scientific adoption of new approach methodologies.

Conclusion

In-vitro toxicology testing is positioned for sustained expansion as regulators, companies, and consumers demand safer, faster, and more human-relevant toxicity assessment. The strongest opportunities are emerging where validated assays, advanced cell models, automation, high-content imaging, and AI-enabled analytics are integrated into reproducible and regulator-ready workflows.

Competitive advantage will depend on scientific validation, data integrity, multi-region compliance expertise, and the ability to translate complex biological outputs into actionable safety decisions. Organizations that invest now in scalable, human-relevant, and evidence-based in-vitro toxicology platforms will be better prepared for the next phase of non-animal testing, new approach methodologies, and precision safety assessment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In-Vitro Toxicology Testing Market, by Service Type

  • 7.1. Biochemical Assays
  • 7.2. Cell Culture Assays
    • 7.2.1. Cell Line Assays
    • 7.2.2. Primary Cell Assays
  • 7.3. Computational Models

8. In-Vitro Toxicology Testing Market, by Technology

  • 8.1. High Throughput Screening
    • 8.1.1. Assay Based
    • 8.1.2. Imaging Based
  • 8.2. Microfluidics
  • 8.3. Organ On Chip
  • 8.4. Three Dimensional Culture

9. In-Vitro Toxicology Testing Market, by Application

  • 9.1. Cosmetics Testing
    • 9.1.1. Ocular Irritation
    • 9.1.2. Skin Irritation
  • 9.2. Drug Discovery
    • 9.2.1. Lead Optimization
    • 9.2.2. Target Validation
  • 9.3. Safety Assessment
    • 9.3.1. Carcinogenicity
    • 9.3.2. Cytotoxicity
    • 9.3.3. Genotoxicity

10. In-Vitro Toxicology Testing Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharma And Biotech

11. In-Vitro Toxicology Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. In-Vitro Toxicology Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. In-Vitro Toxicology Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Becton, Dickinson and Company
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Bio-Techne Corporation
  • 15.6. BioIVT LLC
  • 15.7. Charles River Laboratories International, Inc.
  • 15.8. Creative Bioarray
  • 15.9. ERBC Group
  • 15.10. Eurofins Scientific SE
  • 15.11. Evotec SE
  • 15.12. F. Hoffmann-La Roche AG
  • 15.13. Gentronix Limited
  • 15.14. HD Biosciences Co., Ltd.
  • 15.15. INDIGO Biosciences, Inc.
  • 15.16. Inotiv, Inc.
  • 15.17. InSphero AG
  • 15.18. Intertek Group PLC
  • 15.19. Laboratory Corporation of America Holdings
  • 15.20. LAUS GmbH
  • 15.21. LGC Limited
  • 15.22. Merck KGaA
  • 15.23. Microbac Laboratories Inc.
  • 15.24. Oroxcell
  • 15.25. Promega Corporation
  • 15.26. Qiagen N.V.
  • 15.27. SGS SA
  • 15.28. Thermo Fisher Scientific Inc.
  • 15.29. Toxys, Inc.
  • 15.30. Vimta Labs Ltd.
  • 15.31. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASSAY BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASSAY BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASSAY BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGING BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMAGING BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGING BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROFLUIDICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROFLUIDICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROFLUIDICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGAN ON CHIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORGAN ON CHIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGAN ON CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COSMETICS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COSMETICS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COSMETICS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OCULAR IRRITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OCULAR IRRITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OCULAR IRRITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SKIN IRRITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SKIN IRRITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SKIN IRRITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARCINOGENICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARCINOGENICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARCINOGENICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYTOTOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOTOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYTOTOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOTOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOTOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOTOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 155. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 157. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 159. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 189. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 195. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 197. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 199. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SC